{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T09:08:19Z","timestamp":1778749699924,"version":"3.51.4"},"reference-count":28,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background\/Objectives: Active surveillance (AS) is recommended for men with low-risk prostate cancer to minimize overtreatment while monitoring for disease progression. However, current surveillance strategies rely heavily on repeat biopsies, which are invasive and associated with morbidity. MyProstateScore 2.0\u2014Active Surveillance (MPS2-AS) is a urine-based biomarker test developed to predict progression to Grade Group \u2265 2 (GG \u2265 2) and Grade Group \u2265 3 (GG \u2265 3) prostate cancers in men on AS. The objective of this study was to analytically validate the reproducibility and robustness of MPS2-AS analyte detection and risk score calculation across key laboratory variables. Methods: Analytical precision was evaluated using pooled urine specimens processed using the MPS2-AS laboratory workflow. Eight pooled urine samples were tested in a within-laboratory design across five days, with two runs per day, and two replicates per run. Additional reproducibility studies assessed variability across three QuantStudio\u2122 12K Flex Real-Time PCR Systems and three OpenArray\u2122 chip lots. Ten RNA biomarkers were quantified by RT-PCR and used to calculate the MPS2-AS GG1-2 and GG1-3 risk scores. Variance components were estimated using hierarchical ANOVA. Results: The MPS2-AS analyte measurements demonstrated high precision across within-laboratory testing, with standard deviations ranging from 0.00 to 0.60 and coefficients of variation (%CV) from 0.00 to 4.01%. The reproducibility across qPCR instruments and OpenArray chip lots showed similar robustness, with analyte %CVs of \u22644.57% and \u22644.10%, respectively. These stable analyte measurements translated to reproducible model outputs, with %CV \u2264 10.69% for the GG1-2 risk score and \u22647.20% for the GG1-3 risk score across all tested conditions. No systematic bias was observed between runs, days, instruments, or reagent lots. Conclusions: MPS2-AS demonstrates strong analytical precision and reproducibility for quantifying urinary biomarkers and generating GG1-2 and GG1-3 risk scores. These results support the reliability of MPS2-AS for clinical laboratory implementation and its use as a non-invasive tool to inform biopsy decisions in men with Grade Group 1 prostate cancer undergoing active surveillance.<\/jats:p>","DOI":"10.3390\/diagnostics16101486","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T07:50:15Z","timestamp":1778745015000},"page":"1486","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analytical Validation of MyProstateScore 2.0\u2014Active Surveillance: A Urinary-Based Clinical RT-PCR Prostate Cancer Assay"],"prefix":"10.3390","volume":"16","author":[{"given":"Tabea M.","family":"Setera","sequence":"first","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cameron J.","family":"Seitz","sequence":"additional","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley S.","family":"Moore","sequence":"additional","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Kitchen","sequence":"additional","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Spencer","family":"Heaton","sequence":"additional","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingyi","family":"Cao","sequence":"additional","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob I.","family":"Meyers","sequence":"additional","affiliation":[{"name":"Lynx Dx, Ann Arbor, MI 48108, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/JU.0000000000002758","article-title":"Clinically Localized Prostate Cancer: AUA\/ASTRO Guideline, Part II: Principles of Active Surveillance, Principles of Surgery, and Follow-Up","volume":"208","author":"Eastham","year":"2022","journal-title":"J. Urol."},{"key":"ref_2","unstructured":"National Comprehensive Cancer Network (2026, April 30). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Prostate Cancer. Version 5.2026. National Comprehensive Cancer Network. 2026. Updated 23 January 2026. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e231439","DOI":"10.1001\/jamanetworkopen.2023.1439","article-title":"Time Trends and Variation in the Use of Active Surveillance for Management of Low-risk Prostate Cancer in the US","volume":"6","author":"Cooperberg","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1001\/jamainternmed.2022.7100","article-title":"Use of Active Surveillance vs Definitive Treatment Among Men with Low- and Favorable Intermediate-Risk Prostate Cancer in the US Between 2010 and 2018","volume":"183","author":"Awamlh","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"469","DOI":"10.6004\/jnccn.2025.0052","article-title":"Prostate Cancer, Version 3.2026, NCCN Clinical Practice Guidelines in Oncology","volume":"23","author":"Spratt","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.eururo.2021.12.007","article-title":"Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy","volume":"81","author":"Willemse","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2810","DOI":"10.1200\/JCO.2009.25.7311","article-title":"Prostate-specific antigen kinetics during follow-up are an unreliable trigger for intervention in a prostate cancer surveillance program","volume":"28","author":"Ross","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.eururo.2021.05.001","article-title":"Reliability of Serial Prostate Magnetic Resonance Imaging to Detect Prostate Cancer Progression During Active Surveillance: A Systematic Review and Meta-analysis","volume":"80","author":"Rajwa","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e2128646","DOI":"10.1001\/jamanetworkopen.2021.28646","article-title":"Adoption of New Risk Stratification Technologies Within US Hospital Referral Regions and Association with Prostate Cancer Management","volume":"4","author":"Leapman","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.euf.2017.11.010","article-title":"Prostate Magnetic Resonance Imaging Interpretation Varies Substantially Across Radiologists","volume":"5","author":"Sonn","year":"2019","journal-title":"Eur. Urol. Focus"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.jval.2021.02.009","article-title":"Economic Evaluation of Urine-Based or Magnetic Resonance Imaging Reflex Tests in Men with Intermediate Prostate-Specific Antigen Levels in the United States","volume":"24","author":"Jiao","year":"2021","journal-title":"Value Health"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/j.juro.2011.06.057","article-title":"Complications after prostate biopsy: Data from SEER-Medicare","volume":"186","author":"Loeb","year":"2011","journal-title":"J. Urol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.juro.2013.08.088","article-title":"The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance","volume":"191","author":"Ehdaie","year":"2014","journal-title":"J. Urol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.eururo.2013.05.049","article-title":"Systematic review of complications of prostate biopsy","volume":"64","author":"Loeb","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1007\/s10147-020-01761-3","article-title":"The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN study","volume":"25","author":"Tohi","year":"2020","journal-title":"Int. J. Clin. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.21037\/tau-20-1254","article-title":"Understanding reasons for non-adherence to active surveillance for low-intermediate risk prostate cancer","volume":"10","author":"Beckmann","year":"2021","journal-title":"Transl. Androl. Urol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1097\/JU.0000000000001091","article-title":"Impact of Biopsy Compliance on Outcomes for Patients on Active Surveillance for Prostate Cancer","volume":"204","author":"Detsky","year":"2020","journal-title":"J. Urol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.juro.2018.06.013","article-title":"Long-Term Cancer Specific Anxiety in Men Undergoing Active Surveillance of Prostate Cancer: Findings from a Large Prospective Cohort","volume":"200","author":"Marzouk","year":"2018","journal-title":"J. Urol."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Manceau, C., Fromont, G., Beauval, J.-B., Barret, E., Brureau, L., Cr\u00e9hange, G., Dariane, C., Fiard, G., Gauth\u00e9, M., and Mathieu, R. (2021). Biomarker in Active Surveillance for Prostate Cancer: A Systematic Review. Cancers, 13.","DOI":"10.3390\/cancers13174251"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e235","DOI":"10.1200\/EDBK_159244","article-title":"Active Surveillance of Prostate Cancer: Use, Outcomes, Imaging, and Diagnostic Tools","volume":"35","author":"Tosoian","year":"2016","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1001\/jamaoncol.2024.0455","article-title":"Development and Validation of an 18-Gene Urine Test for High-Grade Prostate Cancer","volume":"10","author":"Tosoian","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1097\/JU.0000000000004421","article-title":"Clinical Validation of MyProstateScore 2.0 Testing Using First-Catch, Non-Digital Rectal Examination Urine","volume":"213","author":"Tosoian","year":"2025","journal-title":"J. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Meyers, J.I., Schatz, T.M., Seitz, C.J., Botbyl, R., Moore, B.S., Crafts, B.G., Kitchen, J.R., and Heaton, S. (2025). Analytical Validation of MyProstateScore 2.0. Diagnostics, 15.","DOI":"10.3390\/diagnostics15070923"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Pekala, K.R., Bergengren, O., Eastham, J.A., and Carlsson, S.V. (2023). Active surveillance should be considered for select men with Grade Group 2 prostate cancer. BMC Urol., 23.","DOI":"10.1186\/s12894-023-01314-6"},{"key":"ref_25","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2014). EP05-A3: Evaluation of Precision of Quantitative Measurement Procedures, CLSI. [3rd ed.]."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Seabold, S., and Perktold, J. (2010). Statsmodels: Econometric and statistical modeling with Python. Proceedings of the 9th Python in Science Conference, SciPy.","DOI":"10.25080\/Majora-92bf1922-011"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00345-021-03622-8","article-title":"Active surveillance for prostate cancer: Selection criteria, guidelines, and outcomes","volume":"40","author":"Walker","year":"2022","journal-title":"World J. Urol."},{"key":"ref_28","unstructured":"US Food and Drug Administration (2026, March 13). Summary of Safety and Effectiveness Data (SSED): IsoPSA Assay, Available online: https:\/\/www.accessdata.fda.gov\/cdrh_docs\/pdf20\/P200048B.pdf."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/10\/1486\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T08:12:59Z","timestamp":1778746379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/16\/10\/1486"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":28,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["diagnostics16101486"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics16101486","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]}}}